A statistically significant difference also existed in the expression levels of WT1 mRNA in PB and BM between the IPSS-R relatively low-risk group(extremely low-risk + low-risk)and the relatively high-risk group(medium risk + high risk + extremely high risk)MDS patients(PB: 2.60±0.76 vs 3.48±0.91, P<0.05; BM: 3.50±0.82 vs 3.89±0.97, P<0.05). This evidence concerns the gene WT1 and myelodysplastic syndrome.